v3.22.4
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Operating activities        
Net loss $ (8,061,398) $ (9,808,625) $ (34,179,634) $ (45,167,731)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 62,383 63,996 257,286 236,864
Amortization of right-of-use asset 251,486 94,880 809,030 841,299
Stock-based compensation 307,030 599,907 1,649,686 5,137,068
Common stock issued for services 42,500 42,500 467,500
Foreign currency exchange (gain) loss, net 781,546 (116,924) 509,652 144,085
Gain on extinguishment of debt     (960,790)
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets 202,785 270,956 1,323,584 613,432
Other long-term assets 27,784 (380,083) 49,854
Accounts payable and accrued liabilities 472,903 (1,076,281) (1,381,199) (2,561,215)
Accrued compensation related 91,641 166,712 56,322 35,528
Operating lease liabilities (262,794) (105,373) (845,483) (629,928)
Net cash used in operating activities (6,126,634) (9,868,252) (32,138,339) (41,794,034)
Investing activities        
Purchases of property and equipment     (244,857) (304,603)
Purchase of intangible assets     (495,000)
Net cash used in investing activities     (244,857) (799,603)
Financing activities        
Proceeds from issuance of common stock through ESPP     2,100 9,973
Proceeds from issuance of common stock and/or warrants     57,004,412
Payment of financing and offering costs (66,469) (39,794) (4,434,441)
Proceeds from exercise of stock options     202,800 636,993
Proceeds from exercise of warrants     4,792,951
Purchase of shares under CGP and Sirtex stock purchase agreements     5,836,731
Principal payments on note payable (276,688) (367,124) (1,325,560) (619,105)
Tax withholdings paid on equity awards (2,646) (28,119) (47,515) (238,976)
Tax shares sold to pay for tax withholdings on equity awards 2,466 27,623 46,346 220,490
Proceeds from co-promotion agreement     5,000,000
Net cash used in financing activities (343,337) (367,620) (1,161,623) 68,209,028
Effect of exchange rate changes on cash and cash equivalents (100,078) (8,606) (106,674) (18,620)
Net decrease in cash and cash equivalents (6,570,049) (10,244,478) (33,651,493) 25,596,771
Cash and cash equivalents, at beginning of period 12,299,740 45,951,233 45,951,233 20,354,462
Cash and cash equivalents, at end of period 5,729,691 35,706,755 12,299,740 45,951,233
Supplemental disclosure for cash flow information:        
Interest 11,081 8,045 20,925 10,302
Income taxes 2,969 4,992
Noncash investing and financing transactions:        
Expiration of warrants 223,225 329,099
Decrease in right-of-use assets and operating lease liabilities resulting from contract modification 482,946 338,819
Amounts accrued for offering costs $ 188,028    
Note issued for insurance premium     $ 1,027,986 $ 1,355,919